Yuhan (YUHNF) Other Current Liabilities: $87.04 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Yuhan Other Current Liabilities?

Yuhan YUHNF 80 Other Current Liabilities is $87.04 Mil as of Mar. 2026. GuruFocus rates YUHNF with a GF Score™ of 80/100. The stock has 5 warning signs investors should review.

Yuhan's other current liabilities for the quarter that ended in Mar. 2026 was $87.04 Mil.

Yuhan's quarterly other current liabilities increased from Sep. 2025 ($125.56 Mil) to Dec. 2025 ($132.53 Mil) but then declined from Dec. 2025 ($132.53 Mil) to Mar. 2026 ($87.04 Mil).

Yuhan's annual other current liabilities declined from Dec. 2023 ($145.61 Mil) to Dec. 2024 ($118.80 Mil) but then increased from Dec. 2024 ($118.80 Mil) to Dec. 2025 ($132.53 Mil).

Yuhan Other Current Liabilities Related Terms

Yuhan Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Yuhan's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yuhan Other Current Liabilities Chart

Yuhan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 99.09 108.44 145.61 118.80 132.53

Yuhan Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 103.55 129.13 125.56 132.53 87.04

Yuhan Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $87.04 Mil mean?
Yuhan (YUHNF) has a Other Current Liabilities of $87.04 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Yuhan.
Is Yuhan's Other Current Liabilities too high?
Yuhan's current Other Current Liabilities is $87.04 Mil. Overall, Yuhan has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Yuhan's Other Current Liabilities compare to ZTS and UTHR?
Yuhan's Other Current Liabilities of $87.04 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Yuhan. Yuhan's current Other Current Liabilities is $87.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yuhan stock overvalued right now?
Yuhan (YUHNF) has a current Other Current Liabilities of $87.04 Mil. The current Other Current Liabilities is $87.04 Mil. Yuhan's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Yuhan (YUHNF), the current Other Current Liabilities is $87.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yuhan Business Description

Other Exchanges 000105:Korea000100:Korea
Address 74 Noryangjin-ro, Daebang-dong, Dongjak-gu, Seoul, KOR
Yuhan Corp is a pharmaceutical company. The core business of the company is classified as primary and specialty care, dietary supplements, household and animal care, and contract manufacturing of active pharmaceutical ingredients. The company offers one-stop custom synthesis services from research and development to commercial production of active pharmaceutical products (APIs) and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets.